



# BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**ESPS manuscript NO:** 24107

**Title:** Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancer

**Reviewer's code:** 00503849

**Reviewer's country:** Taiwan

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2016-01-09 16:24

**Date reviewed:** 2016-01-16 14:12

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

The manuscript was well written and organized. The contents of the manuscript can provide useful information to the readers. I recommend publishing this manuscript.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**ESPS manuscript NO:** 24107

**Title:** Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancer

**Reviewer's code:** 00503832

**Reviewer's country:** Taiwan

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2016-01-09 16:24

**Date reviewed:** 2016-01-21 21:04

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

The authors comprehensively reviewed the roles of lipid mediators especially on  $\omega$ -3 PUFA and resolvins in the stages of acute and chronic inflammation and several types of cancer. The work is excellent and good writing. However, they may have to put more effort in order to improve the article. 1. Although EPA or DHA in fish oil could be metabolized to form respective resolvins, they failed to provide much clear discussion regarding the correlation between resolvins and  $\omega$ -3 PUFA in clinical studies in the section of "Lipid mediators in inflammatory disease". 2. The authors had written four paragraphs in the section of "Lipid mediators in inflammatory disease". The first paragraph briefly described several types of cancers caused by viral infection, autoimmune conditions and chronic inflammation. They also used the second and third paragraphs to discuss the correlation of  $\omega$ -3 PUFA and risk factors of colorectal and breast cancer. However, they only wrote the fourth paragraph (8 lines) to discuss how resolvins influences the progress of cancer in clinical studies. Since the objective of this review paper is to review the roles of resolvins in inflammation and related diseases, the author need to add more information regarding the suppressive or



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

protective effect of resolvins on cancer progress in clinical studies. 3. Although the authors give the title to emphasize their main aim is to describe the lipid mediators, only type 1 resolvins and their upstream  $\omega$ -3 PUFA are discussed in the text. I suggest the authors may change the title to specify their main aim on type 1 resolvins.



**ESPS PEER-REVIEW REPORT**

**Name of journal:** World Journal of Clinical Cases

**ESPS manuscript NO:** 24107

**Title:** Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancer

**Reviewer's code:** 00289581

**Reviewer's country:** United States

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2016-01-09 16:24

**Date reviewed:** 2016-01-25 09:34

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

**COMMENTS TO AUTHORS**

Clinical implications of anti-inflammatory lipid mediators in inflammatory diseases and cancer  
 Authors: Kazuki Moro, Masayuki Nagahashi, Rajesh Ramanathan, Kazuaki Takabe, Toshifumi Wakai  
 This review is a discussion of the importance and consequences of lipid mediators in the response to inflammation. Recommend: Consider a more indebt discussion on the historical prospective of why and how Resolvins were discovered. This should follow the introduction. The active phase of inflammation is described but recommend more detail in the chronic phase of inflammation, ie., Efferocytosis. Are there studies to show that Resolvins stop the progression of chronic disease? if so, recommend detail this in the review. There is mention only once of Lipoxin. I recommend further definition and description. There are several series of resolvins and your description of the D and E series and Aspirin triggering Resolvins confusing. I would add a Table for clarification.